Advertisement

Treatment With ADT May Be Linked to Higher Risk of Heart Failure in Patients With Prostate Cancer

Advertisement

Key Points

  • Incidence rates of heart failure per 100 person-years within a 1-year follow-up period were 4.00 and 1.89 for those treated with ADT and those not treated with ADT, respectively.
  • The HR of heart failure among those treated with ADT was 1.72 compared with those not treated with ADT.
  • In the propensity score‐matched cohort study, the adjusted HR for heart failure among patients treated with ADT was 1.92 compared with propensity score–matched nonusers.

Androgen-deprivation therapy (ADT) use was associated with a higher risk of heart failure in a study of patients with prostate cancer, according to findings published by Kao et al in The Journal of Clinical Pharmacology

Study Methods, Findings

Study authors used data from the Taiwan Longitudinal Health Insurance Database 2005. They then identified 1,244 patients with prostate cancer who were treated with ADT as the study cohort, and 1,806 patients with prostate cancer who were not treated with ADT as the comparison cohort. They performed a propensity score–matched cohort study, tracking each patient for 1 year from the index date.

Incidence rates of heart failure per 100 person-years within a 1-year follow-up period were 4.00 (95% confidence interval [CI] = 2.95–5.30) and 1.89 (95% CI = 1.30–2.66) for those treated with ADT and those not treated with ADT, respectively. The hazard ratio (HR) of heart failure among those treated with ADT was 1.72 (95% CI = 1.08–2.73) compared with those not treated with ADT. In the propensity score-matched cohort study, the adjusted HR for heart failure among patients treated with ADT was 1.92 (95% CI = 1.15–3.18) compared with propensity score–matched nonusers.

“The results of our study provide information for [patients with] prostate cancer to be aware of the potential heart failure risk of receiving ADT,” the authors wrote. “We recommend that clinicians should counsel their patients regarding modifiable heart failure risk factors, suggest they improve their lifestyle, and further provide relevant cardiovascular examination for [patients with] prostate cancer receiving ADT.”

Disclosure: See study authors’ full disclosures at onlinelibrary.wiley.com.

The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.


Advertisement

Advertisement



Advertisement